Statin Treatment in Patients With Asthma

• Status: Terminated
• Trial end date: 2015-06-01
• Target enrollment: 0
• Participant gender: All

Summary

Asthma is a chronic respiratory condition characterized by bronchial hyper-responsiveness secondary to abnormal inflammation of the lung. Steroids remain the most effective treatment for this condition. The lipid lowering agents statins have been found to have anti-inflammatory properties. This study is to test the hypothesize that statins will decrease bronchial hyperresponsiveness and inflammation, leading to improved symptoms in patients with asthma.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Queen's University
• Collaborators: Ontario Lung Association; The Physicians' Services Incorporated Foundation
• Treatments: Atorvastatin; Atorvastatin Calcium

Criteria

Inclusion Criteria:

• Age ≥ 18 years

• Moderate to severe asthma based on Canadian Asthma Consensus Report

• Objective evidence of airway hyper-responsiveness (reversible airflow obstruction or positive methacholine challenge in previous two years

• On chronic maintenance inhaled corticosteroid therapy.

Exclusion Criteria:

• Asthma exacerbation within preceding 3 months necessitating any escalation of maintenance medications

• Chronic oral prednisone use

• Other respiratory, inflammatory and autoimmune disorder

• Abnormal baseline creatinine kinase, liver transaminases, or renal disease

• History of coronary artery disease, hyperlipidemia, or other condition requiring statin therapy